Firm at a glance
Affinity Equity Partners is a platform private equity firm founded in 1998 with five offices across Asia, per its website [S1]. The firm reported approximately USD 14 billion of assets and funds under management as of January 2026 [S1].
What they buy
Based on publicly disclosed transactions, Affinity Equity Partners appears to focus on middle-market and growth-stage companies across the Asia-Pacific region [S2][S3][S4]. Recent activity suggests investment interest spanning consumer brands, healthcare services, and food production sectors. The firm’s transaction history indicates a pattern of building platforms in fragmented Asian markets and executing exits through strategic sales or public market transactions.
Portfolio
No current portfolio companies were identified in publicly available sources as of January 2026. The firm’s recent activity has consisted primarily of exits rather than new platform acquisitions.
Recent activity (last 24 months)
– **May 2025**: Acquired Golden Fresh group, a food production business [S2]
– **February 2026**: Exited Burger King Japan [S3]
– **November 2025**: Completed a second transaction related to Burger King Japan [S3]
– **September 2024**: Exited Island Hospital Sdn Bhd, a Malaysian healthcare provider [S3]
– **April 2024**: Exited PT Industri Jamu dan Farmasi Sido Muncul Tbk, an Indonesian pharmaceutical and traditional medicine manufacturer [S3]
How this firm fits a seller
Affinity Equity Partners appears positioned for business owners seeking a buyer with deep regional expertise in Asian markets. The firm’s recent transaction pattern shows multiple exits over the past 24 months, suggesting active portfolio management and realization activity. For sellers in consumer-facing sectors or healthcare services with operations or growth potential in Asia, the firm’s geographic footprint and reported capital base may provide relevant expansion resources. The Golden Fresh acquisition in 2025 indicates continued appetite for new platform investments despite concurrent exit activity.
Sources
[S1] https://affinityequity.com/about-us (as of 2026-01-15)
[S2] https://www.dcadvisory.com/news-deals-insights/deal-announcements/dc-advisory-advises-the-shareholders-of-golden-fresh-group-on-its-sale-to-affinity-equity-partners/ (as of 2025-05-09)
[S3] https://affinityequity.com/news (as of 2026-02-19)
[S4] https://affinityequity.com (as of 2026-01-15)
Frequently asked questions
Does Affinity Equity Partners buy consumer and food businesses?
Public records indicate the firm has invested in consumer-facing businesses, including its May 2025 acquisition of Golden Fresh group in the food production sector [S2] and its prior ownership of Burger King Japan, which it exited in early 2026 [S3]. These transactions suggest appetite for branded consumer and food-related platforms in Asian markets.
What companies has Affinity Equity Partners acquired recently?
The most recent publicly disclosed acquisition was Golden Fresh group in May 2025 [S2]. Prior to that, the firm’s recent activity consisted primarily of portfolio exits, including Burger King Japan, Island Hospital Sdn Bhd, and PT Industri Jamu dan Farmasi Sido Muncul Tbk [S3].
Where is Affinity Equity Partners based and how big is the firm?
The firm operates five offices across Asia, per its website, though specific city locations were not disclosed in available public materials [S1]. Affinity Equity Partners reported approximately USD 14 billion of assets and funds under management as of January 2026 [S1].
Is Affinity Equity Partners still actively acquiring?
Yes, the firm completed an acquisition of Golden Fresh group in May 2025, indicating active deal execution within the past 12 months [S2]. This acquisition occurred alongside multiple portfolio exits during the same period, suggesting ongoing investment activity.
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.